Free Trial
NASDAQ:ENVB

Enveric Biosciences 3/25/2024 Earnings Report

Enveric Biosciences logo
$1.17 -0.04 (-3.30%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.18 +0.01 (+0.50%)
As of 05/30/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enveric Biosciences EPS Results

Actual EPS
-$21.90
Consensus EPS
-$23.25
Beat/Miss
Beat by +$1.35
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Enveric Biosciences' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Enveric Biosciences Earnings Headlines

Enveric Biosciences announces results from EB-003 trial
Dollar Collapse Warning: Protect Your Wealth NOW
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned. If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

View Enveric Biosciences Profile

More Earnings Resources from MarketBeat